Heart Failure (HF) is a common disease that affects an estimated global population of over 40 million. It is the most frequent cause of hospitalizations in patients over the age of 65, placing a considerable financial and social burden on patients, healthcare providers, and care providers. Accurate clinical assessment of HF and cost-effective management strategies are critical in improving patient outcomes and reducing the socioeconomic burden of this disease.

This educational podcast activity is brought to you by Ortho Clinical Diagnostics, Inc., and is not certified for continuing medical education. Ortho Clinical Diagnostics, Inc. sponsors the program, and the speaker must present information following applicable FDA requirements

About Our Speaker:

VIPLabTech
Dr. Christopher deFilippi

Vice Chair of Academic Affairs, Inova Heart and Vascular Institute (IHVI)

Fairfax, VA

Dr. Christopher deFilippi is a distinguished cardiologist who currently works at the Inova Heart and Vascular Institute (IHVI) in Fairfax, Virginia as the Vice Chair of Academic Affairs.

In his oversight of clinical research, he has built IHVI to be a national leader in site-based research. He serves on the Editorial boards of Circulation, JACC and JACC: Heart Failure. Henis an Associate Editor for the Journal of Applied Laboratory Medicine. His research is focused on evaluating in-vitro diagnostics and proteomics discovery for diagnosis, prognosis, and therapy guidance across the spectrum of health from detection of preclinical cardiovascular disease to diagnosis and treatment in the critically ill.

By listening to this podcast edition you will get the answers to:

  • What are the causes and symptoms of heart failure?
  • How is heart failure diagnosed?
  • What are the advantages of implementing NT-proBNP as part of the diagnostic strategy?
  • What are the differences between the biomarkers BNP and NT-proBNP?